Synapse - Dean Bajorin

Search Within

Dean Bajorin

Results (660)

Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer

Journal Article

Latham, A.; Srinivasan, P.; Kemel, Y.; Shia, J.; Bandlamudi, C.; Mandelker, D.; Middha, S.; Hechtman, J.; Zehir, A.; Dubard-Gault, M.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer

Journal Article

Li, Q.; Damish, A. W.; Frazier, Z.; Liu, D.; Reznichenko, E.; Kamburov, A.; Bell, A.; Zhao, H.; Jordan, E. J.; Gao, S. P.; more...
Clinical Cancer Research (2019)

Fulltext@MSK | Save

Genomic differences between “primary” and “secondary” muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy

Editorial

Pietzak, E. J.; Zabor, E. C.; Bagrodia, A.; Armenia, J.; Hu, W.; Zehir, A.; Funt, S.; Audenet, F.; Barron, D.; Maamouri, N.; more...
European Urology (2019)

Fulltext@MSK | Save

Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)

Meeting Abstract

Vuky, J.; Balar, A. V.; Castellano, D. E.; O'Donnell, P. H.; Grivas, P.; Bellmunt, J.; Powles, T.; Bajorin, D. F.; Hahn, N. M.; De Wit, R.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT)

Meeting Abstract

McHugh, D. J.; Funt, S.; Silber, D.; Knezevic, A.; Patil, S.; O'Donnell, D.; Tsai, S.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts)

Meeting Abstract

Funt, S.; McHugh, D. J.; Tsai, S.; O'Donnell, D.; Knezevic, A.; Patil, S.; Silber, D.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Pembrolizumab (pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial

Meeting Abstract

Fradet, Y.; Bellmunt, J.; De Wit, R.; Vaughn, D. J.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)

Meeting Abstract

Feldman, D. R.; Hu, J.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Appleman, L. J.; Milowsky, M. I.; Patil, S.; Bromberg, M.; Nolan, P.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

DNA damage repair (DDR) germline mutations in patients (Pts) with urothelial carcinoma (UC)

Meeting Abstract

Carlo, M. I.; Vijai, J.; Mandelker, D.; Kemel, Y.; Regazzi, A. M.; Zhang, L.; Stadler, Z. K.; Walsh, M. F.; Cadoo, K. A.; Solit, D. B.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Estimation of tumor-derived mutant allele fractions in cfDNA by shallow whole genome sequencing and fragment size analysis

Meeting Abstract

Yang, J.; Marass, F.; Ulz, P.; Shady, M.; Cheng, M. L.; Kothari, P.; Gedvilaite, E.; Somnay, S.; Shukla, N.; Modak, S.; more...
Cancer Research (2018)

Fulltext@MSK | Save